Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-M17D1 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BL-M17D1, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jun 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-M17D1 | BL M17D1|BLM17D1 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | Limited information is currently available on BL-M17D1, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jun 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06714617 | Phase I | BL-M17D1 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |